10-Q: Prestige Consumer Healthcare Q3 Earnings Decline Amid Acquisitions

Prestige Consumer Healthcare reports a decline in Q3 net income and revenues, impacted by supply chain issues and a significant supplier loan write-off, despite strategic acquisitions.

Summary

• Total revenues for the three months ended December 31, 2025, decreased by $6.9 million, or 2.4%, to $283.4 million compared to the same period in 2024.
• Net income for the three months ended December 31, 2025, was $46.7 million, a decrease of $14.3 million, or 23.5%, from $61.0 million in the prior year.
• Diluted earnings per share (EPS) for the three months ended December 31, 2025, decreased to $0.97 from $1.22 in the prior year.
• For the nine months ended December 31, 2025, total revenues decreased by $34.2 million, or 4.1%, to $807.1 million, and net income decreased by $28.1 million, or 17.1%, to $136.4 million.
• The company completed the acquisition of Pillar5 Pharma, Inc., a sterile ophthalmic manufacturer and Clear Eyes supplier, on December 18, 2025, for $111.9 million.
• The acquisition of Feminax was completed on October 31, 2025, with a purchase price of $13.9 million allocated entirely to intangible assets.
• A supplier loan of $10.3 million was written off during the three and nine months ended December 31, 2025, contributing to a significant increase in other expense, net.
• Net cash provided by operating activities increased by $25.1 million to $214.8 million for the nine months ended December 31, 2025, primarily due to the timing of working capital.
• The company repurchased 2,327,134 shares of common stock for $155.6 million during the nine months ended December 31, 2025, with $92.9 million remaining under the current authorization.
• Gross profit margin remained constant at 55.5% for the three months but increased to 55.7% for the nine months ended December 31, 2025, primarily due to a favorable product mix in North American OTC Healthcare.
• The effective tax rate increased to 24.5% for the three months and 29.2% for the nine months ended December 31, 2025, mainly due to establishing a taxable presence in a new state.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing with a moderately negative sentiment. While strategic acquisitions and share repurchases are positive, the significant declines in core financial metrics (revenue, net income, EPS) and persistent supply chain issues, exacerbated by a large supplier loan write-off, indicate operational headwinds.

Positives

• Net cash provided by operating activities increased by $25.1 million to $214.8 million for the nine months ended December 31, 2025, compared to the prior year.
• Interest expense, net, decreased for both the three-month ($0.8 million decrease) and nine-month ($6.0 million decrease) periods, driven by lower average indebtedness and cost of borrowing.
• The company completed two strategic acquisitions: Pillar5 Pharma, Inc. for $111.9 million and Feminax for $13.9 million, enhancing manufacturing capabilities and brand portfolio.
• A share repurchase program is active, with $92.9 million remaining under the $300.0 million authorization, demonstrating a commitment to returning capital to shareholders.
• Gross profit as a percentage of total revenues increased to 55.7% for the nine months ended December 31, 2025, from 55.2% in the prior year, primarily due to a favorable product mix in North American OTC Healthcare.
• The company remains in compliance with all financial and restrictive covenants under its debt facilities as of December 31, 2025.

Negatives

• Total revenues decreased by 2.4% for the three months and 4.1% for the nine months ended December 31, 2025, compared to the prior year periods.
• Net income declined significantly by 23.5% for the three months and 17.1% for the nine months ended December 31, 2025.
• Diluted EPS decreased by 20.5% for the three months and 15.2% for the nine months ended December 31, 2025.
• A $10.3 million supplier loan write-off significantly increased 'other expense, net' for both the three and nine months ended December 31, 2025.
• General and administrative expenses increased by $3.5 million for the three months and $5.0 million for the nine months, primarily due to an increase in the allowance for doubtful accounts pertaining to one specific customer, as well as compensation and acquisition-related costs.
• Revenues in the Eye & Ear Care category experienced substantial decreases in both North American OTC Healthcare (down 9.5% for 3 months, 21.9% for 9 months) and International OTC Healthcare (down 50.1% for 3 months, 30.4% for 9 months) due to limited ability to supply demand for Clear Eyes.
• International OTC Healthcare segment's gross profit as a percentage of revenues decreased to 55.9% for the three months and 54.5% for the nine months, primarily due to increased inflation costs and product mix.

Risks

• Disruptions in the supply of sourced goods or components, including shortages, delays, and backorders for certain ingredients and products, particularly eye care products.
• Dependence on third-party manufacturers, with a decrease in the percentage of externally produced gross sales covered by long-term contracts (from 73% to 56% for the nine months ended December 31, 2025).
• Price increases for raw materials, labor, energy, transportation, and other input costs due to a high inflationary environment.
• Economic uncertainty, including evolving fiscal policy, changes in interest rates, geopolitical events, and trade restrictions, which could affect demand for products and increase costs.
• Changes in consumer purchasing patterns, including a shift to online purchasing, and changes in retailer purchasing patterns.
• Concentration of revenues from a limited number of top brands (approximately 38% of gross revenues) and major customers like Walmart (18-20%) and Amazon (15-19%).
• Potential for material adverse effects on business, financial condition, and results of operations from natural disasters, performance issues with third-party distribution managers, or labor shortages at facilities.
• Assets are comprised virtually entirely of goodwill and intangibles, which are subject to impairment charges based on adverse operating results or changes in discount rates.
• The level of indebtedness ($1.0 billion outstanding) and the restrictions imposed by financing agreements on operations.

Future Outlook

The company expects economic conditions to remain highly volatile and uncertain, potentially putting pressure on prices and supply, and affecting product demand. Management anticipates continued compliance with financial and restrictive debt covenants for the next twelve months. The impact of recently issued accounting pronouncements (ASU 2024-03 and ASU 2023-09) on future financial statement disclosures is currently being evaluated, but the OBBBA tax act is not expected to have a material impact on the estimated annual effective tax rate.

Management Comments

• Management expects economic conditions will continue to be highly volatile and uncertain, put pressure on prices and supply, and could affect demand for our products.
• We have continued to see changes in the purchasing patterns of our consumers, including a shift in many markets to purchasing our products online.
• The volatile environment has impacted the supply of labor and raw materials and exacerbated rising input costs.
• We have and may continue to experience shortages, delays and backorders for certain ingredients and products, difficulty scheduling shipping for our products, as well as price increases from many of our suppliers.
• Certain of our third-party manufacturers are currently having, and have had in the past, difficulty meeting demand, which is and has caused shortages of our products, particularly eye care products.
• We expect further shortages will continue to have a negative impact on our sales.
• Management anticipates that in the normal course of operations, we will be in compliance with the financial and restrictive covenants during the next twelve months.

Industry Context

StockSavvy.ai notes that Prestige Consumer Healthcare's performance reflects broader challenges within the OTC healthcare sector, particularly the persistent global supply chain constraints, inflationary pressures on input costs, and evolving consumer purchasing patterns towards online channels. The decline in revenue, especially in the Eye & Ear Care category due to supply limitations, highlights specific vulnerabilities that could be exacerbated across the industry. While strategic acquisitions like Pillar5 Pharma aim to mitigate supply chain risks and expand capabilities, the immediate financial results indicate that these headwinds are currently outweighing growth initiatives. The company's reliance on a few major retailers and a significant third-party supplier also underscores concentration risks common in the consumer goods space.

Comparison to Industry Standards

• NA. The filing does not provide specific comparable company data or industry benchmarks to assess Prestige Consumer Healthcare's results against global industry standards or specific competitors' performance.

Legal Proceedings

• The company is involved from time to time in routine legal matters and other claims incidental to its business.
• Management believes the resolution of these matters, taking reserves into account, will not be material to financial condition or results of operations.

Stakeholder Impact

• Shareholders: Impacted by declining EPS and net income, though partially offset by ongoing share repurchase program.
• Customers: May experience product shortages and delays, particularly for eye care products, potentially affecting brand loyalty and availability.
• Suppliers: One specific supplier was subject to a $10.3 million loan write-off, indicating potential financial stress or disputes.
• Employees: Stock-based compensation costs are recognized, and general and administrative expenses increased partly due to compensation costs.

Next Steps

• Continue to evaluate the impact of recently issued FASB ASUs (2024-03 and 2023-09) on Consolidated Financial Statement disclosures.
• Monitor pending legislation and implementation by countries regarding the OECD global minimum tax rules.
• Assess the impact of the One Big Beautiful Bill Act (OBBBA) on the estimated annual effective tax rate.
• Negotiate long-term contracts with certain key manufacturers to mitigate supply chain risks.
• Management anticipates continued compliance with financial and restrictive covenants under debt facilities.

Key Dates

Recommendation

While Prestige Consumer Healthcare is actively managing its portfolio through strategic acquisitions and returning capital to shareholders via repurchases, the notable declines in revenue and net income, coupled with persistent supply chain challenges and a significant supplier loan write-off, suggest a 'hold' position. The company faces headwinds from inflation and product shortages, particularly in key categories like Eye & Ear Care, which could continue to impact near-term performance. The long-term outlook depends on successful integration of acquisitions and resolution of supply chain issues.

Keywords

OTC healthcare, consumer health, pharmaceuticals, acquisitions, supply chain, financial results, 10-Q, Prestige Consumer Healthcare, Pillar5 Pharma, Feminax, share repurchase